Market Place
Sourcing Support
Mycovia Presents VIVJOA® Safety Studies At IDSOG 2024
01 Aug 2024 //
PR NEWSWIRE
Mycovia Announces AllianceRx Walgreens Pharmacy as Distributor of VIVJOA®
26 Mar 2024 //
PR NEWSWIRE
Mycovia Announces Partner Jiangsu Hengrui`s Commercial Launch of VIVJOA
07 Feb 2024 //
PR NEWSWIRE
Mycovia Announces Partner Jiangsu Hengrui`s Approval of Oteseconazole Capsules
21 Aug 2023 //
PR NEWSWIRE
Mycovia Phase 3 ultraVIOLET Study Evaluating the Efficacy of VIVJOA in Women
25 Aug 2022 //
BUSINESSWIRE
Mycovia Pharma to Present Topline Results from Two Studies Evaluating VIVJOA
02 Aug 2022 //
BUSINESSWIRE
Mycovia Pharma Announces Publication of Positive PIII Data Evaluating VIVJOA
26 Jul 2022 //
BUSINESSWIRE
Mycovia Pharma Announces U.S. Availability of VIVJOA Capsules
18 Jul 2022 //
BUSINESSWIRE
Mycovia Pharma Announces Positive New Clinical Findings Evaluating VIVJOA
22 Jun 2022 //
BUSINESSWIRE
Mycovia Pharma to Host Product Theater for VIVJOA During 2022 ACOG
05 May 2022 //
BUSINESSWIRE
FDA Approves Mycovia Pharma`s VIVJOA for Recurrent Vulvovaginal Candidiasis
28 Apr 2022 //
BUSINESSWIRE
Mycovia Pharma Announces Completion of Partner Jiangsu Hengrui Pharma’ Phase 3
03 Nov 2021 //
BUSINESSWIRE
Mycovia Pharmaceuticals Announces U.S. FDA Acceptance of Oteseconazole
29 Jul 2021 //
BUSINESSWIRE
Mycovia Announces Presentation of Oteseconazole (VT-1161) Phase 3 Data
29 Jul 2021 //
BUSINESSWIRE
Mycovia’s ultraVIOLET study meets all endpoints in RVVC drug trial
07 Jan 2021 //
CLINICALTRIALSARENA
Mycovia Announces Positive Topline Results from its Third Ph3 Trial
06 Jan 2021 //
BUSINESSWIRE
Mycovia Announces Positive Topline Results from its Third Ph3 (ultraVIOLET)
05 Jan 2021 //
BUSINESSWIRE
Mycovia Announces Positive Topline Results from Ph3 VIOLET Studies
09 Dec 2020 //
BUSINESSWIRE
Mycovia Announces Positive Topline Results from Ph3 VIOLET of Oteseconazole
09 Dec 2020 //
BUSINESSWIRE
Mycovia. Announces Last Patient Completes Final Visit Ph 3 “ultraVIOLET Study”
02 Dec 2020 //
BUSINESSWIRE
Mycovia Last Patient Completes Ph3 “ultraVIOLET Study” for Oteseconazole
02 Dec 2020 //
BUSINESSWIRE
Mycovia Completes Successful Pre-NDA Meeting with FDA for Oteseconazole
12 Nov 2020 //
BUSINESSWIRE
Mycovia Pharmaceuticals, Announces Last Patient Completes Final Visit (VT-1161)
21 Oct 2020 //
BUSINESSWIRE
Mycovia Announces Peer-Reviewed Publication of +VE Study of Oteseconazole
26 Aug 2020 //
BUSINESSWIRE
Mycovia CEO Patrick Jordan Named 2020 Life Sciences CEO of the Year
06 Aug 2020 //
BUSINESSWIRE
Mycovia Pharmaceuticals Completes Enrollment in its Third Phase 3 Clinical Trial
18 Dec 2019 //
BUSINESS WIRE
Mycovia Pharmaceuticals Completes Enrollment in its Third Ph 3 Trial VT-1161
18 Dec 2019 //
BUSINESS WIRE
Mycovia Announces Early Completion for Global Ph3 Clinical Trials for VT-1161
12 Nov 2019 //
BUSINESSWIRE
Tiaki Therapeutics Presents Data on Identification of a Novel Target
21 Oct 2019 //
BUSINESSWIRE
Mycovia Pharmaceuticals Announces Partnership with Gedeon Richter
16 Oct 2019 //
BUSINESSWIRE
